The United Kingdom, long considered a hub for pharmaceutical innovation, is facing an exodus of major pharmaceutical companies. Over the last several months, some of the industry biggest names, including Merck MSD, AstraZeneca, and Eli Lilly, have either cancelled or paused multi-million-pound projects